<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: There is evidence to suggest that <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C virus (HCV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is a high-risk condition for developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are no interventional studies that confirm that HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> causes <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The main aim of this study was to compare the incidence of <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities (<z:mp ids='MP_0002055'>diabetes</z:mp> plus impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>) between HCV-infected patients with or without sustained virological response (SVR) after antiviral therapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Patients with <z:mpath ids='MPATH_458'>normal</z:mpath> fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (&lt;100 mg/dl) with biopsy-proven <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C without <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> and with at least 3 years of follow-up after finishing antiviral therapy were included in the study (n = 234) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received interferon alpha-2b (alone or with ribavirin) for 6 or 12 months according to genotype </plain></SENT>
<SENT sid="5" pm="."><plain>Cumulative incidence of <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities was evaluated by using the Kaplan-Meier method comparing subjects with and without a SVR to antiviral treatment </plain></SENT>
<SENT sid="6" pm="."><plain>A multivariate Cox proportional hazards analysis was performed to explore the variables independently associated with the development of <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: During follow-up, 14 of 96 (14.6%) patients with SVR and 47 of 138 (34.1%) nonsustained responders developed <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities (P = 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with SVR did not develop <z:mp ids='MP_0002055'>diabetes</z:mp> during follow-up, whereas nine cases of <z:mp ids='MP_0002055'>diabetes</z:mp> were detected in nonsustained responders (P = 0.007) </plain></SENT>
<SENT sid="9" pm="."><plain>After adjustment for the recognized predictors of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the hazard ratio for <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities in patients with SVR was 0.48 (95% CI [0.24-0.98], P = 0.04) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our results provide evidence that eradication of HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> significantly reduces the incidence of <z:chebi fb="105" ids="17234">glucose</z:chebi> abnormalities in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C patients </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, this study supports the concept that HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> causes type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>